Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Discovery
Cancer Discovery

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
    • Journal Press Releases
Research Watch

PON2 Promotes Glucose Uptake to Support PDAC Growth and Metastasis

DOI: 10.1158/2159-8290.CD-RW2017-157 Published October 2017
  • Article
  • Info & Metrics
  • PDF
Loading
  • Major finding: PON2 promotes GLUT1-mediated glucose transport, is upregulated in PDAC, and is required for PDAC growth.

  • Mechanism: PON2 depletion promotes anoikis via AMPK-mediated FOXO3A activation and PUMA upregulation.

  • Impact: Activation of the AMPK–FOXO3A–PUMA pathway may suppress PDAC growth and metastasis.


Embedded Image

The glycolytic and glutamine metabolic pathways are deregulated in pancreatic ductal adenocarcinoma (PDAC), but the mechanisms underlying this deregulation are not well understood. Nagarajan and colleagues performed an siRNA screen of metabolic genes overexpressed in patients with PDAC to identify those essential for PDAC tumor growth. Paraoxonase 2 (PON2) was found to be required for the growth of PDAC cells in vitro and in vivo, and cooperated with KRASG12D to accelerate tumor progression. Further, PON2 expression prevented anoikis, to allow enhanced PDAC metastasis. Transcription of PON2 was directly repressed by the tumor suppressor p53; thus, p53 inactivation resulted in PON2 upregulation. Mechanistically, PON2 loss activated the cellular starvation response, leading to AMPK-mediated activation of the tumor suppressive transcription factor FOXO3A, and upregulation of its proapoptotic target gene PUMA, to promote anoikis and suppress PDAC growth and metastasis. Conversely, PON2 overexpression promoted glucose uptake by binding to the glucose transporter GLUT1 and blocking its interaction with the inhibitory protein STOM, thereby supporting PDAC growth and metastasis. Consistent with these findings, depletion of FOXO3A or suppression of AMPK activation could promote tumor growth in PON2-deficient cells and suppress anoikis. In a mouse model of PDAC lung metastasis, PON2 depletion could suppress the growth of established lung tumors. Moreover, the AMPK agonists metformin or AICAR inhibited PDAC colony formation and suppressed tumorigenesis in vivo. Thus, AMPK activation and PON2 inhibition have similar effects in suppressing PDAC tumor growth. The identification of PON2 as an essential regulator of GLUT1-mediated glucose transport for PDAC growth and metastasis suggests that pharmacologic activation of the AMPK–FOXO3A–PUMA pathway may be a therapeutic approach to suppress PDAC growth.

Nagarajan A, Dogra SK, Sun L, Gandotra N, Ho T, Cai G, et al. Paraoxonase 2 facilitates pancreatic cancer growth and metastasis by stimulating GLUT1-mediated glucose transport. Mol Cell 2017;67:685–701.e6.

Notes

Note: Research Watch is written by Cancer Discovery editorial staff. Readers are encouraged to consult the original articles for full details. For more Research Watch, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/content/early/by/section.

  • ©2017 American Association for Cancer Research.
View Abstract
PreviousNext
Back to top
Cancer Discovery: 7 (10)
October 2017
Volume 7, Issue 10
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
PON2 Promotes Glucose Uptake to Support PDAC Growth and Metastasis
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
Citation Tools
PON2 Promotes Glucose Uptake to Support PDAC Growth and Metastasis
Cancer Discov October 1 2017 (7) (10) 1058; DOI: 10.1158/2159-8290.CD-RW2017-157

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
PON2 Promotes Glucose Uptake to Support PDAC Growth and Metastasis
Cancer Discov October 1 2017 (7) (10) 1058; DOI: 10.1158/2159-8290.CD-RW2017-157
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Notes
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Research Watch

  • A Cancer-Germline Antigen Signature Predicts Anti-CTLA4 Resistance
  • Loss of p62 in Adipocytes Promotes Aggressive Prostate Cancer
  • The EZH2 Inhibitor Tazemetostat Is Well Tolerated in a Phase I Trial
Show more 3

Pancreatic Cancer

  • KRASG12D Gene Dosage Drives Pancreatic Tumor Evolution and Progression
  • An Adrenergic–Neurotrophin Feedforward Loop Promotes Pancreatic Cancer
  • Pancreatitis-Induced p62 Accumulation Promotes Pancreatic Cancer
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement